About Elevation Oncology, Inc. - Common stock (ELEV)
Elevation Oncology Inc is a biopharmaceutical company focused on developing targeted therapies for patients with genomically defined cancers. The company is dedicated to understanding the unique genetic drivers of these diseases and aims to create innovative treatment options that address unmet medical needs. By leveraging its expertise in precision medicine and oncology, Elevation Oncology works to advance its clinical pipeline, providing hope to patients with rare and challenging cancer types through personalized and effective therapeutic strategies. Read More
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Elevation Oncology, Inc. (NasdaqCM: ELEV) to Concentra Biosciences, LLC. Under the terms of the proposed transaction, shareholders of Elevation will receive $0.36 in cash per share, plus one non-tradeable contingent value right representing the right to receive: (i) 100% of the closing net cash in excess of $26.4 million; and (ii) 80% of any net proceeds received within five years following closing from any disposition of EO-1022 that occurs within one year following closing. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
BALA CYNWYD, Pa., June 09, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Elevation Oncology, Inc. (NASDAQ: ELEV) to Concentra Biosciences, LLC is fair to Elevation shareholders. Under the terms of the proposed transaction, Elevation shareholders will receive $0.36 in cash per share, plus one non-tradeable contingent value right representing the right to receive: (i) 100% of the closing net cash in excess of $26.4 million; and (ii) 80% of any net proceeds received within five years following closing from any disposition of EO-1022 that occurs within one year following closing.
Intrigued by the market activity in the middle of the day on Thursday? Uncover the key winners and losers of today's session in our insightful analysis.
Elevation Oncology's ADCs target CLDN18.2 and HER3, with EO-3021 showing promising Phase 1 results and a $6.6 billion TAM in gastric and pancreatic cancers.
Elevation Oncology shares dropped after initial data from the Phase 1 trial of EO-3021 showed a 42.8% objective response rate in patients with advanced solid tumors expressing Claudin 18.2. No Grade 4 or 5 adverse events were reported. The company plans further trial expansion in 2025.
